Key facts & figures
- To print this page, please use the File menu or press simultaneously ctrl + p keys.
- Send this page
Sanofi-aventis is a global pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Our business includes two main activities : pharmaceuticals and human vaccines.
- 2007 net sales: €28,052 million +2,8%* versus 2006
- Fourth largest pharmaceutical group in the world and largest one in Europe, based on 2007 sales
Sanofi-aventis has a strong commitment to research and development. We focus on high-growth therapeutic areas representing key public health challenges.
- 2007 R&D budget: €4,537 million +5.5% versus 2006 (excluding the effect of exchange rates)
- Corresponding to 16.2% of net sales
Pharmaceutical business
In the pharmaceutical business, sanofi-aventis counts 15 leading products in terms of net sales ("top 15") in six therapeutic areas: thrombosis, cardiovascular diseases, diabetes, oncology, central nervous system (CNS) and internal medicine.
- 2007 net sales of the pharmaceutical business: €25,274 million +1.7%* versus 2006
- 2007 net sales of the "top 15": €17,071 million +3.2%* versus 2006
- The "top 15" products represent 67.5% of pharmaceutical net sales
| Top 15 | Therapeutic area | 2007 sales
€ million | % change*
(vs. 2006) |
|---|
| Lovenox® | Thrombosis | 2,612 | +13.4% |
|---|
| Plavix® | Thrombosis | 2,424 | +9.5% |
|---|
| Lantus® | Diabetes | 2,031 | +29.0% |
|---|
| Taxotere® | Oncology | 1,874 | +11.9% |
|---|
| Eloxatin® | Oncology | 1,521 | -5.3% |
|---|
| Ambien® / Ambien CR™ / Stilnox® | CNS | 1,250 | -33.1% |
|---|
| Copaxone® | CNS | 1,177 | +17.1% |
|---|
| Aprovel® | Cardiovascular | 1,080 | +7.2% |
|---|
| Tritace® | Cardiovascular | 741 | -23.1% |
|---|
| Allegra® | Internal medicine | 706 | +10.8% |
|---|
| Amaryl® | Diabetes | 392 | -9.5% |
|---|
| Xatral® | Internal medicine | 333 | -2.9% |
|---|
| Actonel® | Internal medicine | 320 | -8.0% |
|---|
| Depakine® | CNS | 316 | +5.7% |
|---|
| Nasacort® | Internal medicine | 294 | +11.8% |
|---|
| TOTAL TOP 15 | | 17,071 | +3.2% |
|---|
In addition to the top 15 products, sanofi-aventis’ global portfolio comprises a wide range of other pharmaceutical products ("base business"), including prescription drugs and products sold over the counter.
- 2007 net sales of the "base business": €8,203 million - 1.5% versus 2006
- The "base business" represents 32.5% of pharmaceutical net sales
Human vaccines business
Sanofi Pasteur, the fully integrated vaccine business of sanofi-aventis, is a world leader in the vaccine industry and holds leading positions in most countries offering the broadest range of vaccines in five areas: influenza, pediatric combinations and poliomyelitis vaccines, adult and adolescent booster vaccines, meningitis as well as travel, endemic and measles, mumps, rubella (MMR) vaccines.
- Net sales 2007 of the vaccines business: €2,778 million +14.5%* versus 2006
| € million | 2007 sales | % change*
(vs. 2006) |
|---|
| Influenza vaccines | 766 | -3.0% |
|---|
| Polio/Whooping Cough/Hib Vaccines | 660 | +5.1% |
|---|
| Meningitis/pneumonia vaccines | 482 | +65.1% |
|---|
| Adult booster vaccine | 402 | +26.8% |
|---|
| Travel vaccines | 327 | +14.7% |
|---|
| Other vaccines | 141 | +23.7% |
|---|
| TOTAL | 2,778 | +14.5% |
|---|
Geographic presence
Sanofi-aventis has a commercial presence in approximately 100 countries, and our products are available in more than 170 countries. Our top five markets in terms of 2007 net sales are the United States, France, Germany, Italy and Japan.
The breakdown of 2007 net sales is the following:
- Europe: 43.4%
- United States: 33.8%
- Other countries (including Japan): 22.8%
| € million | 2007 sales | % change*
(vs. 2006) |
|---|
| Europe | 12,184 | -0.4% |
|---|
| United States | 9,474 | +3.8% |
|---|
| Other countries | 6,394 | +7.8% |
|---|
* Changes in our sales are stated on a “comparable” basis.
